TARGET PharmaSolutions

News

Published On: 3/18/2020

COVID-19 Response

Corona Virus

Based on the current recommendations from the CDC and Governor of North Carolina, the entire TARGET PharmaSolutions staff has transitioned to a remote working environment. During this time, TARGET expects work to continue as usual.

TARGET shares its support to all of those who have been affected by the expanding global corona virus, or COVID-19, outbreak.

Stay up-to-date on the virus from the World Health Organization (WHO): https://www.who.int/emergencies/diseases/novel-coronavirus-2019

-TARGET PharmaSolutions

About TARGET PharmaSolutions

Headquartered in Durham, NC, TARGET PharmaSolutions is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting.  TARGET PharmaSolutions has six disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), TARGET-IBD (inflammatory bowel disease), TARGET-DERM (immune mediated skin conditions) and TARGET-HBV (hepatitis B).

For more information, visit www.targetpharmasolutions.com.

Contact:

Kayla Slake
Marketing Manager

kslake@targetpharmasolutions.com

984.234.0268 ext 205